Anlotinib Hydrochloride in Intra-Abdominal Desmoplastic Small Round Cell Tumor: Case-Based Evidence for Multi-Target TKI Efficacy

Study Background and Research Question

Intra-abdominal desmoplastic small round cell tumor (IADSRCT) is a rare, aggressive sarcoma predominantly affecting young males. First characterized by Gerald and Rosai in 1989, IADSRCT is defined by the presence of the EWS-WT1 translocation and fusion protein. With a five-year survival rate of only 15–30% and no standardized treatment guidelines, current management relies on multimodal approaches combining surgery, chemotherapy, and radiotherapy. However, outcomes remain poor and therapeutic options for relapsed or metastatic disease are limited.

The introduction of multi-target tyrosine kinase inhibitors (TKIs) has transformed the landscape of targeted therapy in diverse malignancies. Anlotinib hydrochloride, an orally bioavailable small-molecule TKI, selectively inhibits VEGFR1–3, FGFR1–4, PDGFRα/β, c-Kit, and Met, targeting critical pathways in tumor angiogenesis and cell proliferation. Despite its demonstrated efficacy in several solid tumor types, its role in rare sarcomas such as IADSRCT was previously unreported. The reference study presents the first case of IADSRCT treated with anlotinib, aiming to evaluate its clinical impact and tolerability in this context.

Key Innovation from the Reference Study

The principal innovation of the case report lies in its demonstration that anlotinib hydrochloride can induce substantial tumor regression in metastatic IADSRCT, a tumor type historically resistant to available therapies. This case provides the first clinical evidence supporting the use of a multi-target tyrosine kinase inhibitor in IADSRCT, thereby expanding the potential utility of anti-angiogenic targeted therapy to this rare sarcoma subtype. The study underscores the translational significance of anlotinib’s broad receptor inhibition profile, suggesting new possibilities for managing tumors with complex angiogenic signaling networks.

Methods and Experimental Design Insights

The study employs a case-based clinical design, supported by both imaging and histopathology. The patient, a 38-year-old male with biopsy-confirmed IADSRCT, initially underwent surgical resection of abdominal and peritoneal masses. Despite six cycles of adjuvant chemotherapy, computed tomography (CT) scans revealed lymph node metastases. At this point, anlotinib hydrochloride was introduced as a targeted therapeutic intervention.

Anlotinib was administered orally, and response was assessed by serial CT imaging. Tumor progression, regression, and patient tolerance were closely monitored, with specific attention to adverse events and laboratory parameters. Histopathological evaluations included immunohistochemistry for classic IADSRCT markers (AE1/AE3, desmin, CD34, and others), with a proliferation index (Ki-67) of 40% supporting the diagnosis.

Core Findings and Why They Matter

After four cycles of anlotinib, the patient experienced marked reduction in metastatic lymph node size, as documented by CT. This objective response was accompanied by clinical stability and manageable side effects, including mild hypertriglyceridemia and fatigue. Importantly, the toxicity profile was controllable and did not necessitate treatment discontinuation. Maintenance therapy with anlotinib resulted in sustained disease control, with the patient remaining in good condition at follow-up.

These findings are significant for several reasons. First, they provide proof-of-concept that multi-target tyrosine kinase inhibition can be effective in IADSRCT, a tumor type for which no prior targeted therapies have shown clear benefit. Second, the use of anlotinib aligns mechanistically with the established role of aberrant angiogenesis and growth factor signaling in sarcoma biology. By inhibiting VEGFR, PDGFR, and FGFR pathways, anlotinib disrupts endothelial cell migration, capillary tube formation, and downstream ERK signaling—all processes implicated in tumor vascularization and growth.

The case also highlights the potential of anlotinib as a maintenance therapy, extending disease control beyond initial response. This is particularly relevant given the high relapse rates and limited durability of standard cytotoxic regimens in IADSRCT.

Protocol Parameters

• Anlotinib dosing: The reference case used oral administration, with dose and schedule adjusted to patient tolerance; specific cycles were monitored by imaging.
• Response monitoring: Serial CT scans before and after four treatment cycles to document tumor regression.
• Safety assessment: Routine laboratory studies (lipids, organ function), symptom tracking (fatigue), and toxicity grading to inform ongoing use.
• Histopathological confirmation: Immunohistochemical analysis for AE1/AE3, desmin, CD34, and Ki-67 as diagnostic markers for IADSRCT, ensuring accurate patient selection.
• Maintenance therapy: Continued anlotinib treatment beyond initial tumor response, with periodic re-evaluation for progression or toxicity.

Comparison with Existing Internal Articles

Internal literature offers additional context for anlotinib hydrochloride’s molecular and translational profile. The review "Anlotinib Hydrochloride: Molecular Insights and Translational Advances" details the compound’s selective inhibition of VEGFR2, PDGFRβ, and FGFR1, emphasizing its capacity to block ERK signaling and angiogenesis in diverse cancer models. This aligns with the clinical findings in IADSRCT, where angiogenic signaling is a central pathogenic feature.

Further, "Anlotinib in Intra-Abdominal Desmoplastic Small Round Cell Tumor: A Case-Based Insight" synthesizes case-based evidence, echoing the reference study’s observation of tumor regression and manageable toxicity. Researchers seeking to model endothelial cell migration inhibition or perform capillary tube formation assays may reference "Enhancing Cancer Research Assays with Anlotinib (hydrochloride)" for protocol optimization and workflow reproducibility in preclinical settings.

Limitations and Transferability

This case report, while groundbreaking, is inherently limited by its single-patient design. The lack of a comparator arm, standardized dosing, and long-term follow-up restricts the generalizability of findings. Moreover, IADSRCT’s biological heterogeneity and rarity preclude immediate extrapolation to broader sarcoma populations.

Nonetheless, the mechanistic rationale—targeting angiogenic and growth factor pathways—remains compelling and may inform future studies in both IADSRCT and other rare, angiogenesis-driven malignancies. Clinical validation in larger cohorts, ideally through multicenter prospective trials, is necessary to confirm efficacy and refine patient selection criteria.

Research Support Resources

For researchers aiming to investigate multi-target tyrosine kinase inhibition or model angiogenesis pathways in vitro, Anlotinib hydrochloride (SKU C8688, APExBIO) is available as a research-use reagent. Its high selectivity for VEGFR2, PDGFRβ, and FGFR1, coupled with low cytotoxicity at functional concentrations, makes it suitable for endothelial migration and capillary tube formation assays, as highlighted in the internal protocol literature. When planning translational or mechanistic studies, researchers can leverage these resources to design robust workflows that parallel clinically meaningful endpoints observed in the reference case report.